Abstract Body

Background: The treatment of Hepatitis C virus (HCV) infection is rapidly evolving from the current standard of care comprised of interferon (IFN)-based triple therapy to IFN free treatment with directly acting antiviral agents (DAAs). Triple therapy with Boceprevir (BOC) or Telaprevir has resulted in improved SVR rates, however adverse events (AEs), pill burden and drug interactions remain significant barriers to successful completion of treatment. The aim of this study was to evaluate the AEs experienced with the present standard of care compared to sofosbuvir + ribavirin (SOF/RBV) in HCV monoinfected, genotype-1 (GT-1) individuals.

Methodology: We retrospectively evaluated HCV monoinfected, treatment naive, GT-1 individuals treated with either BOC/IFN/RBV at the Veterans Affairs Medical Center, Baltimore (n=97) or SOF/RBV in the SPARE clinical trial at the National Institute of Allergy and Infectious Disease (n=60). AEs namely hematologic (hemoglobin, neutrophil and platelet counts); hepatic (alanine transaminase or bilirubin) and renal (eGFR) were measured and graded from 1 (mild) to 4 (severe) according to the DAIDS toxicity table (version 1.0). Comparisons were carried out using the nonparametric Wilcoxon rank sum and Chi square tests using GraphPad Prism 6.0.

Results: The BOC/IFN/RBV cohort was older (58 vs. 55, p=0.0006) male (96% vs. 62%, p<0.0001) and had more advanced liver disease (59% vs. 23%, p<0.0001) (Table 1). The SOF/RBV group had a higher proportion of African Americans (83% vs. 65%, p=0.001). The combination of SOF/RBV was well tolerated, while BOC/IFN/RBV was associated with significantly more AEs, most commonly neutropenia, anemia and low platelets. (Table 1). In the SOF/RBV cohort, 5(8%) patients discontinued treatment early but none (0%) were for AEs while 34 (35%) patients on triple therapy discontinued treatment due to AEs.

Conclusions: SOF/RBV treatment was associated with much fewer side effects than BOC-based triple therapy appearing to be a safer and more tolerable alternative for HCV GT-1 subjects. These results show that emerging IFN/RBV free therapies may enhance patient compliance, allowing treatment of larger numbers of patients.